Raptor Pharmaceutica (RPTP) 7.45 $RPTP Raptor

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Raptor Pharmaceutica (RPTP) 7.45 $RPTP

Raptor Pharmaceutical to Present Data on QUINSAIR(TM) and Other Inhaled Antibiotics at the ERS International Congress
GlobeNewswire - Wed Aug 24, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the European Respiratory Society (ERS) International Congress 2016 and will present data from a systematic literature review and network meta-analysis comparing the efficacy of QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, with other inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis. The presentation will be at the European Respiratory Society (ERS) International Congress in London, United Kingdom, at London EXCEL from Saturday, September 3, to Wednesday, September 7, 2016.
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical Voted A "Best Places to Work" Company in the North San Francisco Bay Area
GlobeNewswire - Thu Aug 18, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11 Annual North Bay Business Journal competition. The results of the best places to work in the North Bay will be featured in the September 19, 2016 publication of the North Bay Business Journal.
RPTP: 7.45 (-0.22)

Raptor Pharmaceuticals (RPTP) in Focus: Stock Up 5.7%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:05AM CDT
Raptor Pharmaceuticals Corp. (RPTP) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
RPTP: 7.45 (-0.22)

Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.44 (+0.01), SYN: 1.64 (unch), RPTP: 7.45 (-0.22), INCY: 81.10 (+0.12)

Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:08PM CDT
Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million
RPTP: 7.45 (-0.22)

ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:54AM CDT
Investor focus will remain on the performance of ACADIA's (ACAD) recently launched Nuplazid.
ACAD: 32.13 (-0.41), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), XLRN: 30.01 (-0.31)

Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:18AM CDT
Our proven model does not conclusively show that Ligand (LGND) is likely to beat earnings estimates this quarter.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), LGND: 103.31 (-1.00), XLRN: 30.01 (-0.31)

Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 234.54 (-2.45), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), TEVA: 50.39 (-0.17)

Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 5:49AM CDT
With no approved products in its portfolio, focus will remain on Juno's (JUNO) pipeline and cash burn.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), JUNO: 29.58 (-1.95), CELG: 106.74 (-0.28)

Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GlobeNewswire - Thu Jul 28, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
GlobeNewswire - Fri Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIR to inhaled tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infections that were presented at the 39 European Cystic Fibrosis Conference in Basel, Switzerland.
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical to Present Data on QUINSAIR(TM) at European Cystic Fibrosis Conference
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:07PM CDT
PROCYSBI Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)

Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 7.45 (-0.22), EBIO: 4.88 (+0.15), PTCT: 8.21 (+0.52), PETX: 8.87 (-0.36), ARRY: 3.43 (-0.17)

Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 7.45 (-0.22)

Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 10:22AM CDT
Image source: Raptor Pharmaceuticals Corp. What: Shares of Raptor Pharmaceuticals Corp.  (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence . ...
RPTP: 7.45 (-0.22)

Raptor Pharmaceutical Launches QUINSAIR(TM) in Europe
GlobeNewswire - Mon Apr 11, 6:05AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR(TM) (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.
RPTP: 7.45 (-0.22)

These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 7.45 (-0.22), TTNP: 5.62 (+0.03), MNKD: 0.80 (+0.10), TLOG: 0.22 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 25

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 86

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 0

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 21

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading

Top 5 Most Recently Viewed Articles

Choice Hotels Unveils Comprehensive Sustainability Efforts

Updated Category News Views 387

Choice Hotels International Launches 2024 Sustainability Report Choice Hotels International, Inc. (NYSE: CHH), a leading global lodging franchisor, has officially released its 2024 Sustainability Report, showcasing its ongoing commitment to environmental sustainability. The report highlights the company's innovative approaches to reducing its carbon footprint and...

Continue Reading
Revitalizing Communities Through Skilled Trades Initiatives

Updated Category News Views 157

Revitalizing Communities Through Skilled Trades Initiatives In an important moment for many towns across America that are striving for renewal, a new initiative has emerged to shine a light on the necessity of skilled trades. The campaign, titled Careers in Manufacturing, is aimed at highlighting how vital these trades are for both local economies and the workforce on the...

Continue Reading
Color Me Mine Celebrates Growth and Franchise Success

Updated Category News Views 344

Color Me Mine Achieves Remarkable Mid-Year Growth Color Me Mine, a leading paint-your-own pottery franchise, is excited to announce significant growth through its studio expansion and franchisee success. The brand is witnessing a thriving landscape of opportunities, fueled by enthusiastic franchise owners who are making their mark in various communities. Studio Expansion...

Continue Reading
Earnings Insights: Companies Set to Report Soon

Updated Category News Views 202

Upcoming Earnings Reports for Major Companies As the earnings season approaches, investors and analysts eagerly anticipate the financial results from several prominent companies. This article highlights some of the key players expected to announce their quarterly results. Companies Reporting Before the Market Opens UP Fintech Holding (TIGR) UP Fintech Holding is projected...

Continue Reading
Cogent Biosciences Shares Insights at Prestigious Healthcare Event

Updated Category News Views 207

Cogent Biosciences Highlights Participation in Major Healthcare Conference Cogent Biosciences, Inc. (Nasdaq: COGT), a pioneering biotechnology company, is ready to showcase its innovative approach to precision medicine at the highly regarded J.P. Morgan Healthcare Conference. Taking place in San Francisco, this annual event is a crucial platform for industry leaders to...

Continue Reading